Join us on this episode of The Oncology Journal Club Podcast as we dissect the latest research that point to new standards of care. Join our esteemed Hosts, Professor Craig Underhill, Dr. Kate Clarke and Professor Christopher Jackson for the low down on the latest oncology papers.Craig looks at how three-agent regimens have revolutionised the treatment of metastatic hormone-sensitive prostate cancer.  Kate asks how alcohol affects lethal prostate cancer risk.  And CJ explores the promising results of adjuvant pembrolizumab in resected renal cell carcinoma with his typical in-depth, high-speed and highly nuanced analysis. Then we shift gears to our popular Quick Bites section (and yes, CJ is at the crackers again!). We look at the halted KeyVibe Adjuvant Melanoma Study, a Chinese trial on oesophageal squamous cell carcinoma, a small trial on dual tyrosine kinase inhibitors for BRAF mutant stage 3 melanoma, the TOPAS1 trial on divalimab in advanced biliary tract cancer and rural clinical trial enrolment.  As always, The OJC team provide a robust analysis of the latest findings in oncology research. Tune in for a comprehensive, insightful and entertaining review of cutting-edge oncology developments.For papers, bios and other links visit the Show Notes on our website.For the latest oncology news visit www.oncologynews.com.au.We invite healthcare professionals to join The Oncology Network for free - you'll also receive our free weekly publication The Oncology Newsletter.The Oncology Podcast - An Australian Oncology Perspective